Acute Pain - Pipeline Insight, 2024

This “Acute Pain- Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Acute Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute Pain: Understanding

Acute Pain: Overview

Pain is an unpleasant sensory and emotional experience usually arising from actual or potential tissue damage. Acute pain can be a difficult medical problem to diagnose and treat. It may be caused by many events or circumstances. Symptoms can last hours, days, or weeks and are commonly associated with tissue injury, inflammation, a surgical procedure, childbirth, or a brief disease process. Other types of pain may be classified as chronic (pain of long duration), neuropathic (pain resulting from damage to nerves), psychogenic (pain not due to visible signs of disease or injury), or cancer-related (effects of a malignant disease on the body). Pain is the most common reason for admission to the emergency department (ED), comprising more than 40% of the over 100 million ED visits annually. Acute pain tends to be of a relatively short duration. The most common signs and symptoms of acute pain include: Sharp pain, throbbing, burning, stabbing pain, tingling, weakness and numbness. It’s important to note that acute pain can affect much more than an injured body part. If a person is experiencing debilitating pain, the effects will bleed into other areas of the person’s life. It’s very common for a person who’s suffering from severe pain to be unable to get restful sleep because of it, or lose their appetite. Depending on the location of the pain, it can also cause breathing difficulties, and in a worst-case scenario, could result in addiction to pain medication or even depression. Diagnosing and treating the cause of pain is an essential aspect of treatment. Initial treatment may include some of the following: Resting the affected part of the body, application of heat or ice, nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, or naproxen; or acetaminophen, physical therapy and Exercise.

Acute Pain- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Pain pipeline landscape is provided which includes the disease overview and Acute Pain treatment guidelines. The assessment part of the report embraces, in depth Acute Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Pain R&D. The therapies under development are focused on novel approaches to treat/improve Acute Pain.

Acute Pain Emerging Drugs Chapters

This segment of the Acute Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Pain Emerging Drugs

NTM-001: Neumentum NTM-001 is Neumentum’s lead product candidate: a novel, alcohol-free formulation of the powerful NSAID ketorolac, in a pre-mixed bag designed for 24-hours of continuous infusion following surgery. It is being evaluated to manage moderately severe acute pain that requires analgesia at the opioid-level, usually in a postoperativesetting.

CGT 1507: CGene TechOtenaproxesul is a novel nonsteroidal anti-inflammatory drug (“NSAID”) that releases hydrogen sulfide. Antibe is leveraging the drug’s remarkable potency, gastrointestinal (“GI”) protection and overall safety profile for use in acute pain indications. Otenaproxesul, is being developed as a safer non-opioid analgesic for post-operativepain.

TRPA1 Antagonist: Algomedix Algomedix is developing a non-opioid, non-addictive, novel TRPA1 antagonist for the treatment of acute and chronic pain. Algomedix is focused on the advancement of a novel, small molecule TRPA1 antagonist for the treatment of pain. This clinical candidate offers the potential for a next-generation analgesic devoid of the addiction and abuse liabilities, as well as other adverse effects inherent in the opioid class ofdrugs.

Acute Pain: Therapeutic Assessment

This segment of the report provides insights about the different Acute Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Pain

There are approx. 25+ key companies which are developing the therapies for Acute Pain. The companies which have their Acute Pain drug candidates in the most advanced stage, i.e. phase III include, Neumentum.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acute Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Pain drugs.

Acute Pain Report Insights

• Acute Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Pain drugs?
• How many Acute Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Pain?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Neumentum
• CGeneTech
• Algomedix
• TREMEAU PHARMACEUTICALS
• Vertex Pharmaceuticals
• Kures, Inc.
• Jiangsu Hengrui Medicine Co.
• SiteOne Therapeutics
• Mylan Specialty, LP
• Viatris Inc.
• Tetra Bio-Pharma
• Scilex Pharmaceuticals, Inc.

Key Products

• NTM-001
• CGT 1507
• TRPA1 Antagonist
• TRM-362
• CL-108
• CLP-417
• VX-548
• KUR 101
• VX-708
• HR 18042
• ST-2427
• MR 107A 02
• PPP001
• SP-103

This product will be delivered within 1-3 business days.